Reporting Another Profitable Year, Genomic Health Considers Prostate Cancer Dx Next Big Opportunity | GenomeWeb

By Turna Ray

Genomic Health this week reported a 16 percent increase in 2011 revenues and disclosed advances in the development of its Oncotype DX test in prostate cancer, which it considers to be the next big revenue opportunity beyond its successful breast cancer franchise.

The company also announced plans to launch a subsidiary focused on applying genomic information to clinical practice.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Science this week: new chromatin imaging approach, and more.

University of Wisconsin researchers uncover a mutation linked to Mauriac syndrome, which affects some children with type 1 diabetes.

Theranos has hired executives to oversee compliance and regulatory issues, the Wall Street Journal reports.

Chinese researchers to embark on a trial using a CRISPR/Cas9-based immunotherapy next month, Nature News reports.